Cituis Oncology Files 8-K/A Amendment on Asset Acquisition

Ticker: CTOR · Form: 8-K/A · Filed: Aug 26, 2024 · CIK: 1851484

Sentiment: neutral

Topics: amendment, acquisition, financial-statements

TL;DR

Cituis Oncology filed an 8-K/A amendment for asset acquisition, formerly TenX Keane.

AI Summary

Cituis Oncology, Inc. filed an amendment (8-K/A) on August 26, 2024, to its Form 8-K dated August 12, 2024. This amendment pertains to the completion of an acquisition or disposition of assets and includes financial statements and exhibits. The company was formerly known as TenX Keane Acquisition, with a name change occurring on March 15, 2021.

Why It Matters

This filing provides updated information regarding asset transactions and financial disclosures for Cituis Oncology, Inc., which may impact investors' understanding of the company's current operational status.

Risk Assessment

Risk Level: low — The filing is an amendment to a previous report and primarily concerns asset acquisition and financial statements, not a new material event.

Key Players & Entities

FAQ

What is the purpose of this 8-K/A filing?

This 8-K/A filing is an amendment to a previously filed Form 8-K, specifically addressing the completion of an acquisition or disposition of assets and including financial statements and exhibits.

What was Cituis Oncology, Inc. formerly known as?

Cituis Oncology, Inc. was formerly known as TenX Keane Acquisition.

When did the company change its name from TenX Keane Acquisition?

The company's name change from TenX Keane Acquisition occurred on March 15, 2021.

What is the earliest event date reported in this filing?

The earliest event date reported in this filing is August 12, 2024.

What is the filing date of this amendment?

This amendment (8-K/A) was filed on August 26, 2024.

Filing Stats: 1,159 words · 5 min read · ~4 pages · Grade level 12.1 · Accepted 2024-08-26 16:15:34

Filing Documents

financial statements provided under Item 9.01 — Financial Statements and Exhibits in the Original Report to include

financial statements provided under Item 9.01 — Financial Statements and Exhibits in the Original Report to include: (i) Management's Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months ended June 30, 2024; (ii) the unaudited balance sheets as of June 30, 2024 and September 30, 2023, the unaudited statements of operations for the three and nine months ended June, 2024 and 2023, the unaudited statements of changes in shareholders' equity for the three and nine months ended June 30, 2024 and 2023, and the unaudited statements of cash flows for the nine months ended June 30, 2024 and 2023; and (iii) the unaudited pro forma condensed combined financial information of SpinCo and the Company as of and for the six months ended June 30, 2024 and year ended December 31, 2024. Except as described above, no other changes have been made to the Original Report and this Amendment No. 1 does not modify or update any other information in the Original Report. Information not affected by the changes described above is unchanged and reflects the disclosures made at the time of the Original Report. 1 Item 2.01. Completion of Acquisition or Disposition of Assets. FINANCIAL INFORMATION Reference is made to the disclosure set forth in Item 9.01 of this Amendment No. 1 concerning the financial information of the Company and such information is incorporated herein by reference. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The information set forth in Exhibit 99.2 to this Amendment No. 1 is incorporated herein by reference. FINANCIAL The information set forth in sections (a), (b) and (d) of Item 9.01 of this Amendment No. 1 is incorporated herein by reference. Item9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (a)

Financial Statements of Businesses Acquired

Financial Statements of Businesses Acquired Included as Exhibit 99.1 and incorporated herein by reference are the unaudited financial statements of SpinCo as of and for the nine months ended June 30, 2024 and 2023. Included as Exhibit 99.2 and incorporated herein by reference is Management's Discussion and Analysis of Financial Condition and Results for the three and nine months ended June 30, 2024. (b) Unaudited Pro Forma Financial Information The unaudited pro forma condensed combined financial information of SpinCo and the Company as of and for six months ended June 30, 2024 and the year ended December 31, 2023 is attached hereto as Exhibit 99.3 and is incorporated herein by reference. (d)Exhibits Exhibit No. Description of Exhibits 99.1 Unaudited Financial Statements of SpinCo as of and for the Nine Months Ended June 30, 2024 and 2023. 99.2 Management's Discussion and Analysis of Financial Condition and Results of Operations for the Three and Nine Months Ended June 30, 2024. 99.3 Unaudited Pro Forma Condensed Combined Financial Information as of and for the Six Months Ended June 30, 2024 and 2023. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 26, 2024 CITIUS ONCOLOGY, INC. By: /s/ Leonard Mazur Name: Leonard Mazur Title: Chief Executive Officer (Principal Executive Officer) 3

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on Read The Filing